Given the tumor suppressive function of COX-2 inhibitors in breast cancer, combined with the implications of COX-2 enzymatic activity in CSCs in other types of cancer, we tested the use of COX-2 inhibitor in BCSC self-renewal. The gene discussed is PTGS2; the disease is neoplasm.